Although previous studies suggest positive outcomes with novel salvage therapies for patients with relapsed/refractory classic Hodgkin’s lymphoma who are eligible for autologous stem cell transplant, the efficacies and outcomes of different salvage therapies in this patient population remain unestablished.
Investigators analyzed data on consecutive patients with autologous stem cell transplant-eligible relapsed/refractory classic Hodgkin’s lymphoma at three Mayo Clinic sites between January 2008 and May 2020, identifying six groups of salvage therapy: ifosfamide, carboplatin and etoposide, bendamustine/brentuximab, brentuximab vedotin (BV), gemcitabine-based therapy, checkpoint inhibitor, and others.
No differences in progression-free or overall survival rates were observed by salvage therapy type. However, BV maintenance (BVm) after autologous stem cell transplant was associated with increased progression-free survival (hazard ratio [HR], 0.3) when compared with no BVm, and higher number of salvage therapies was associated with lower overall survival (HR, 2.0) upon multivariate modeling.
